FAQ

Yanink N Caro-Vega

Suggest Changes
Jean William Pape28
Juan G Sierra-Madero27
Pedro E. Cahn19
Brenda E Crabtree-Ramírez18
Jaime F Andrade-Villanueva17
28Juan G Sierra-Madero
16Brenda E Crabtree-Ramírez
15Pablo F. Belaunzarán-Zamudio
13Denis Padgett
12Jean William Pape

Filter Results:

  • Full text PDF available (12)

Publication Year

2011
2018
  • This year (2)
  • Last 5 years (14)
  • Last 10 years (18)

Publication Type

Co-author

Journals and Conferences

Learn More
Multiple human papillomavirus infections are highly prevalent in the anal canal of human immunodeficiency virus-positive men who have sex with men
BACKGROUND Anal cancer has become one of the most common non-AIDS-defined tumors among Human Immunodeficiency Virus-positive (HIV+) individuals, and a rise in its incidence among HIV+ Men who have… (More)
Did Universal Access to ARVT in Mexico Impact Suboptimal Antiretroviral Prescriptions?
Background. Universal access to antiretroviral therapy (ARVT) started in Mexico in 2001; no evaluation of the features of ARVT prescriptions over time has been conducted. The aim of the study is to… (More)
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
BACKGROUND The efficacy of antiretroviral therapy (ART) has been established through clinical trials (CTs). However, selection bias and differences can limit their applicability to the general… (More)
Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America
Background Efavirenz (EFV) and boosted protease inhibitors (bPIs) are still the preferred options for firstline antiretroviral regimens (firstline ART) in Latin America and have comparable short-term… (More)